Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Int Immunopharmacol ; 122: 110626, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37459785

RESUMO

BACKGROUND: Accurate and rapid laboratory diagnosis of COVID-19 infection and its deterioration is one of the milestones of pandemic control. Therefore, this study aimed to compare the diagnostic and prognostic accuracy of the mainly used laboratory biomarkers (WBCS, neutrophil and lymphocyte percentages, CRP, ferritin, IL-6, D-dimer, procalcitonin, and LDH) in the sera of severe COVID-19 Egyptian patients to assess the most appropriate biomarker used in severe COVID-19 patients. METHODS: A total of 180 unvaccinated severe COVID-19 patients were enrolled in our study. Demographic data, hospitalization time, medical history, oxygen saturation, respiratory rate, oxygen supply, laboratory findings, and thorax tomography of the patients were obtained retrospectively from the hospital's electronic information system. RESULTS: Our results revealed that the levels of neutrophil percentage, CRP, IL-6, PCT, and LDH were significantly increased while lymphocyte percentage was significantly decreased among nonsurvival severe COVID-19 patients when compared with survival ones. By using ROC curve analysis, IL-6, and LDH are the most sensitive and specific markers for the prediction of bad prognosis and mortality among severe COVID-19 patients with 100% and 93% sensitivity and 93.7% specificity; respectively. IL-6 and LDH showed significant correlations with the other parameters, which suggested their association with the severity of COVID-19. CONCLUSION: By using survival severe COVID-19 patients as a control group, our results showed that blood neutrophil percentage, serum CRP, IL-6, PCT, and LDH were significantly increased in non-survivors as compared to survivors. As biomarkers, our results revealed that IL-6 and LDH are good predictors of mortality among severe COVID-19 patients.


Assuntos
COVID-19 , Humanos , Interleucina-6 , Estudos Retrospectivos , Biomarcadores , Lactato Desidrogenases , Proteína C-Reativa/análise , L-Lactato Desidrogenase
3.
Pathology ; 54(1): 104-110, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-34838331

RESUMO

Identification of human miRNAs involved in coronavirus-host interplay is important due to the current COVID-19 pandemic. Therefore, this study aimed to measure the circulating plasma miR-155 expression level in COVID-19 patients and healthy controls to investigate its roles in the pathogenesis and severity of COVID-19 disease and to assess its usefulness as a clinical biomarker for the detection of COVID-19 disease and the severity of infection. A total of 150 COVID-19 patients and 50 controls were enrolled into our study. Beside the routine laboratory work and chest computed tomography (CT) scans of COVID-19 patients, plasma miR-155 expression level was measured using reverse transcription quantitative real-time PCR (RT-qPCR) technique. Our results demonstrated increased miR-155 expression level in COVID-19 patients compared to controls, in severe compared to moderate COVID-19 patients, and in non-survival compared to survival COVID-19 patients. miR-155 expression level also had significant correlation with clinicopathological characteristics of COVID-19 patients such as chest CT findings, CRP, ferritin, mortality, D-dimer, WBC count, and lymphocytes and neutrophils percentages. Also, our results showed that the area under the curve (AUC) for miR-155 was 0.986 with 90% sensitivity and 100% specificity when used as a biomarker for the detection of COVID-19 disease; while in detection of severity of COVID-19 disease, AUC for miR-155 was 0.75 with 76% sensitivity and specificity. From these results we can conclude that miR-155 has a crucial role in the pathogenesis and severity of COVID-19; also, it could be a good diagnostic clinical biomarker for the detection of COVID-19 disease and the severity of infection.


Assuntos
Biomarcadores/sangue , COVID-19/sangue , COVID-19/diagnóstico , MicroRNAs/sangue , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , SARS-CoV-2 , Sensibilidade e Especificidade
4.
Arch Med Sci ; 14(1): 115-121, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29379541

RESUMO

INTRODUCTION: In humans, vitamin D has been shown to play a role in infectious diseases, but its association with acquisition and a complicated course of febrile urinary tract infections (UTIs) has not been investigated. We aimed to investigate the association between 25-hydroxyvitamin D (25(OH)D3) levels and the risk of first time febrile UTI in children. MATERIAL AND METHODS: This prospective case-control study included 50 children with first febrile UTI, with no risk factors for UTI, and 50 age- and sex-matched healthy siblings as controls. White blood cell count, serum C-reactive protein, calcium, phosphorus, alkaline phosphatase and parathormone were measured in all studied children. Vitamin D status was determined by measuring plasma 25(OH)D3 level. Deficiency was defined as a plasma 25(OH)D3 level ≤ 25 nmol/l. RESULTS: Children with UTI had significantly lower mean serum levels of 25(OH)D3 (10.5 ±2.7 nmol/l) than those of controls (25.9 ±5.6 nmol/l) (p < 0.05). Patients with lower UTI had significantly higher serum levels of 25(OH)D3 compared to those with acute pyelonephritis (12.4 ±2.59 vs. 8.2 ±3.2 nmol/l; p < 0.001). Mean serum levels of 25(OH)D3 were significantly lower (p = 0.001) in the female patients compared with males, and this difference was not found within the control group. Multivariate analysis showed that a serum 25(OH)D3 level of ≤ 25 nmol/l is associated with UTI (OR = 1.94, 95% CI: 1.61-2.82; p = 0.04). CONCLUSIONS: Vitamin D deficiency (≤ 25 nmol/l) was an independent risk factor for UTI in children.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...